Sight Sciences (SGHT)
(Delayed Data from NSDQ)
$5.45 USD
+0.03 (0.55%)
Updated May 14, 2024 04:00 PM ET
After-Market: $5.42 -0.03 (-0.55%) 7:06 PM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
Price, Consensus and EPS Surprise
SGHT 5.45 +0.03(0.55%)
Will SGHT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for SGHT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SGHT
Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Tops Revenue Estimates
Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Tops Revenue Estimates
SGHT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sight Sciences (SGHT) to Expand in Europe With New Launch
Ekso Bionics (EKSO) Reports Q3 Loss, Tops Revenue Estimates
Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates
Other News for SGHT
Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference
Sight Sciences, Inc. (SGHT) Q1 2024 Earnings Call Transcript
Sight Sciences GAAP EPS of $0.33, revenue of $19.3M
Sight Sciences price target raised by $1 at Piper Sandler, here's why
Piper Sandler Sticks to Their Hold Rating for Sight Sciences (SGHT)